Does fluoxetine (Prozac) decrease semen volume or impair sperm production in adult males?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 16, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Fluoxetine Does Impair Sperm Quality and May Reduce Semen Volume

Based on the most recent and highest-quality evidence, fluoxetine negatively affects multiple sperm parameters including sperm concentration, motility, morphology, and DNA integrity, though the FDA label indicates no impairment of fertility was observed in animal studies at therapeutic doses. 1

Direct Evidence from FDA Drug Label

The FDA label for Prozac (fluoxetine) states that "impairment of fertility in adult animals at doses up to 12.5 mg/kg/day (approximately 1.5 times the MRHD on a mg/m² basis) was not observed" in two fertility studies conducted in adult rats. 1 However, this animal data does not directly address semen volume or comprehensive sperm quality parameters in humans.

Human Evidence Shows Significant Impairment

Meta-Analysis Findings (2022)

A systematic review and meta-analysis of 222 male participants demonstrated that SSRIs, including fluoxetine, significantly reduced:

  • Normal sperm morphology (p = 0.002)
  • Sperm concentration (p = 0.02)
  • Sperm motility (p = 0.04)
  • Increased sperm DNA fragmentation index (p = 0.0002)

Critically, SSRIs did NOT significantly affect semen volume (p = 0.89). 2 The impacts on morphology and concentration were observed within 3 months of SSRI use.

Recent In Vitro Studies (2025)

The most recent in vitro human sperm studies reveal fluoxetine's mechanisms of harm:

At therapeutic concentrations found in blood and seminal fluid, fluoxetine:

  • Consistently decreased progressive motility over 24 hours
  • Promoted fluctuations in reactive oxygen species (ROS) levels
  • Induced premature sperm capacitation
  • Did NOT affect viability, mitochondrial membrane potential, acrosome reaction, or chromatin/DNA integrity at low doses 3

At higher concentrations, fluoxetine significantly:

  • Reduced motility, viability, mitochondrial membrane potential, acrosome and chromatin integrity
  • Decreased total antioxidant capacity (TAC)
  • Increased malondialdehyde (MDA), ROS, and DNA fragmentation
  • Increased expression of apoptotic genes (CASPASE8, CASPASE9, BAX) and decreased anti-apoptotic BCL2 4

Animal Studies Show Reversible Damage

A 2025 mouse study using clinically relevant doses (20 mg/kg/day for 4 weeks) demonstrated:

  • Significantly reduced mating and fertility indices
  • Decreased sperm count and motility
  • Increased sperm deformities
  • Testicular damage with immature germ cells and reduced seminiferous tubule integrity

Importantly, reproductive function showed partial recovery by 4 weeks post-discontinuation and near-complete normalization by 8 weeks after stopping fluoxetine. 5

Mechanism of Action

Fluoxetine appears to impair sperm production through androgenic failure. Studies show it targets Leydig cells, reducing:

  • 17β-HSD6 steroidogenic activity
  • Serum testosterone levels
  • Sertoli cell and peritubular myoid cell integrity
  • This leads to disrupted spermatogenesis and increased germ cell death 6

The drug increases oxidative stress by elevating ROS while decreasing antioxidant defenses, and upregulates UCHL1 (ubiquitin carboxyl-terminal hydrolase L1), which appears to regulate germ cell death in an androgen-dependent manner. 6

Clinical Context from Guidelines

While the AUA guidelines on premature ejaculation note that SSRIs including fluoxetine are used therapeutically to delay ejaculation 7, and the AACE guidelines acknowledge that "most psychotropic drugs can affect libido or erectile function" 8, neither guideline specifically addresses semen production or sperm quality concerns.

The 2024 AUA/ASRM male infertility guideline emphasizes avoiding gonadotoxic therapies and preserving fertility 9, but does not specifically list fluoxetine among documented gonadotoxins.

Clinical Recommendations

For men of reproductive age or those planning conception:

  • Fluoxetine impairs sperm quality through multiple mechanisms (oxidative stress, apoptosis, reduced testosterone)
  • Semen volume appears preserved, but concentration, motility, morphology, and DNA integrity are compromised
  • Effects occur within 3 months of use
  • Recovery is possible but may take 2-3 months after discontinuation based on animal data
  • Consider alternative antidepressants with less impact on sexual/reproductive function if fertility is a concern
  • If fluoxetine is essential, counsel patients about temporary fertility impairment and potential need for longer time-to-conception

Common Pitfall: The FDA label's statement about "no impairment of fertility" in animal studies is misleading—it refers to the ability to achieve pregnancy at supratherapeutic doses, not comprehensive sperm quality parameters that are clearly affected in human studies.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.